• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
Benign Prostatic Hyperplasia - Pipeline Review, H2 2012 Product Image

Benign Prostatic Hyperplasia - Pipeline Review, H2 2012

  • ID: 2233761
  • August 2012
  • 116 pages
  • Global Markets Direct

Benign Prostatic Hyperplasia – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Benign Prostatic Hyperplasia - Pipeline Review, H2 2012', provides an overview of the Benign Prostatic Hyperplasia therapeutic pipeline. This report provides information on the therapeutic development for Benign Prostatic Hyperplasia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Benign Prostatic Hyperplasia. 'Benign Prostatic Hyperplasia - Pipeline Review, H2 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Benign Prostatic Hyperplasia.
- A review of the Benign Prostatic READ MORE >

2
List of Tables 7
List of Figures 8
Introduction 9
REPORT COVERAGE 9
Benign Prostatic Hyperplasia Overview 10
Therapeutics Development 11
An Overview of Pipeline Products for Benign Prostatic Hyperplasia 11
Benign Prostatic Hyperplasia Therapeutics under Development by Companies 13
Benign Prostatic Hyperplasia Therapeutics under Investigation by Universities/Institutes 16
Late Stage Products 17
Comparative Analysis 17
Mid Clinical Stage Products 18
Comparative Analysis 18
Early Clinical Stage Products 19
Comparative Analysis 19
Discovery and Pre-Clinical Stage Products 20
Comparative Analysis 20
Benign Prostatic Hyperplasia Therapeutics – Products under Development by Companies 21
Benign Prostatic Hyperplasia Therapeutics – Products under Investigation by Universities/Institutes 23
Companies Involved in Benign Prostatic Hyperplasia Therapeutics Development 24
Allergan, Inc. 24
Eli Lilly and Company 25
Light Sciences Oncology, Inc. 26
Aphios Corporation 27
Astellas Pharma Inc. 28
Dong-A Pharmaceutical Co., Ltd. 29
Kissei Pharmaceutical Co., Ltd. 30
Ranbaxy Laboratories Limited 31
Bayer AG 32
Addex Pharmaceuticals 33
AEterna Zentaris Inc. 34
Nymox Pharmaceutical Corporation 35
Ahn-Gook Pharmaceutical Co., Ltd. 36
Quest PharmaTech Inc. 37
Plethora Solutions Holdings plc 38
Protox Therapeutics Inc. 39
Ajanta Pharma Limited 40
AndroScience Corporation 41
NovaLead Pharma Pvt. Ltd. 42
EndoCeutics, Inc. 43
World of Health Biotech Co.Ltd 44
Pherin Pharmaceuticals, Inc. 45
Ausio Pharmaceuticals, LLC 46
Benign Prostatic Hyperplasia – Therapeutics Assessment 47
Assessment by Monotherapy Products 47
Assessment by Combination Products 48
Assessment by Route of Administration 49
Assessment by Molecule Type 52
Drug Profiles 54
AEZS-115 - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
ADX68692 - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
Sperol - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
NX-1207 - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
ASC-JM.X2 - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
Aptocine - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
VLDM01 - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
PRX302 - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
AUS-131 - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
Pomegranate Tablets - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
SL052 - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
Botox - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
Zydena - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
Zydena - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
AG SDT102 - Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
solifenacin succinate + tamsulosin hydrochloride - Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
Tadalafil + Finasteride - Drug Profile 78
Product Description 78
Mechanism of Action 78
R&D Progress 78
Silodosin - Drug Profile 80
Product Description 80
Mechanism of Action 80
R&D Progress 80
MCS-2 - Drug Profile 81
Product Description 81
Mechanism of Action 81
R&D Progress 81
Levitra - Drug Profile 83
Product Description 83
Mechanism of Action 83
R&D Progress 83
PH45 - Drug Profile 85
Product Description 85
Mechanism of Action 85
R&D Progress 85
TUC202 - Drug Profile 86
Product Description 86
Mechanism of Action 86
R&D Progress 86
Tamsulosin + Meloxicam - Drug Profile 87
Product Description 87
Mechanism of Action 87
R&D Progress 87
ASP4901 - Drug Profile 88
Product Description 88
Mechanism of Action 88
R&D Progress 88
KSO-0400 - Drug Profile 89
Product Description 89
Mechanism of Action 89
R&D Progress 89
ASP0306 - Drug Profile 90
Product Description 90
Mechanism of Action 90
R&D Progress 90
RBx 11528 - Drug Profile 91
Product Description 91
Mechanism of Action 91
R&D Progress 91
Antiandrogens - Drug Profile 92
Product Description 92
Mechanism of Action 92
R&D Progress 92
Benign Prostatic Hyperplasia Therapeutics – Drug Profile Updates 93
Benign Prostatic Hyperplasia Therapeutics – Discontinued Products 105
Benign Prostatic Hyperplasia Therapeutics - Dormant Products 106
Benign Prostatic Hyperplasia – Product Development Milestones 108
Featured News & Press Releases 108
Jul 31, 2012: Nymox Pharma Reports Positive Results From Combined Statistical Analysis Of Long Term Follow-Up Studies Of BPH Drug 108
Jul 17, 2012: Nymox Pharma Provides Update On Phase III Pivotal Trials Of NX-1207 108
Jul 11, 2012: Nymox Pharma Completes Enrollment In Phase III Benign Prostatic Hyperplasia Re-Injection Study Of NX-1207 109
Jul 09, 2012: Nymox Announces Positive Safety Monitoring Committee Results For Phase III NX02-0020 Repeat Injection Study For NX-1207 109
May 21, 2012: Nymox Presents New Positive Data On NX-1207 At American Urological Association Annual Meeting 110
May 16, 2012: Nymox To Present Data On NX-1207 At American Urological Association Annual Meeting 111
Apr 26, 2012: Nymox Pharma Announces Positive Safety Monitoring Committee Results For Phase III NX-1207 Trials For Benign Prostatic Hyperplasia 111
Apr 24, 2012: Nymox To Present Data On NX-1207 At American Urological Association Annual Meeting 112
Apr 11, 2012: FDA Announces Changes To Professional Labels For Proscar 113
Mar 28, 2012: Protox Completes Dosing Of Final Cohort Of Patients In Transrectal Study 113
Appendix 115
Methodology 115
Coverage 115
Secondary Research 115
Primary Research 115
Expert Panel Validation 115
Contact Us 116
Disclaimer 116

List of Tables
Number of Products Under Development for Benign Prostatic Hyperplasia, H2 2012 11
Products under Development for Benign Prostatic Hyperplasia – Comparative Analysis, H2 2012 12
Number of Products under Development by Companies, H2 2012 14
Number of Products under Development by Companies, H2 2012 (Contd..1) 15
Number of Products under Investigation by Universities/Institutes, H2 2012 16
Comparative Analysis by Late Stage Development, H2 2012 17
Comparative Analysis by Mid Clinical Stage Development, H2 2012 18
Comparative Analysis by Early Clinical Stage Development, H2 2012 19
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2012 20
Products under Development by Companies, H2 2012 21
Products under Development by Companies, H2 2012 (Contd..1) 22
Products under Investigation by Universities/Institutes, H2 2012 23
Allergan, Inc., H2 2012 24
Eli Lilly and Company, H2 2012 25
Light Sciences Oncology, Inc., H2 2012 26
Aphios Corporation, H2 2012 27
Astellas Pharma Inc., H2 2012 28
Dong-A Pharmaceutical Co., Ltd., H2 2012 29
Kissei Pharmaceutical Co., Ltd., H2 2012 30
Ranbaxy Laboratories Limited, H2 2012 31
Bayer AG, H2 2012 32
Addex Pharmaceuticals, H2 2012 33
AEterna Zentaris Inc., H2 2012 34
Nymox Pharmaceutical Corporation, H2 2012 35
Ahn-Gook Pharmaceutical Co., Ltd., H2 2012 36
Quest PharmaTech Inc., H2 2012 37
Plethora Solutions Holdings plc, H2 2012 38
Protox Therapeutics Inc., H2 2012 39
Ajanta Pharma Limited, H2 2012 40
AndroScience Corporation, H2 2012 41
NovaLead Pharma Pvt. Ltd., H2 2012 42
EndoCeutics, Inc., H2 2012 43
World of Health Biotech Co.Ltd, H2 2012 44
Pherin Pharmaceuticals, Inc., H2 2012 45
Ausio Pharmaceuticals, LLC, H2 2012 46
Assessment by Monotherapy Products, H2 2012 47
Assessment by Combination Products, H2 2012 48
Assessment by Stage and Route of Administration, H2 2012 51
Assessment by Stage and Molecule Type, H2 2012 53
Benign Prostatic Hyperplasia Therapeutics – Drug Profile Updates 93
Benign Prostatic Hyperplasia Therapeutics – Discontinued Products 105
Benign Prostatic Hyperplasia Therapeutics – Dormant Products 106
Benign Prostatic Hyperplasia Therapeutics – Dormant Products (Contd..1) 107

List of Figures
Number of Products under Development for Benign Prostatic Hyperplasia, H2 2012 11
Products under Development for Benign Prostatic Hyperplasia – Comparative Analysis, H2 2012 12
Products under Development by Companies, H2 2012 13
Products under Investigation by Universities/Institutes, H2 2012 16
Late Stage Products, H2 2012 17
Mid Clinical Stage Products, H2 2012 18
Early Clinical Stage Products, H2 2012 19
Discovery and Pre-Clinical Stage Products, H2 2012 20
Assessment by Monotherapy Products, H2 2012 47
Assessment by Combination Products, H2 2012 48
Assessment by Route of Administration, H2 2012 49
Assessment by Stage and Route of Administration, H2 2012 50
Assessment by Molecule Type, H2 2012 52
Assessment by Stage and Molecule Type, H2 2012 53

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos